In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

Phase

Condition

Hematologic Neoplasms

Red Blood Cell Disorders

Bone Neoplasm

Treatment

[68Ga]-Pentixafor

Clinical Study ID

NCT05093335

21-356

Ages > 18
All Genders

Study Summary

The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).

Eligibility Criteria

Inclusion

Inclusion Criteria:

Twenty patients with histologically proven treatment-naïve, therapy-refractory or relapsed blood cancers meeting the below criteria will be included:

Indolent B- or T-cell Non-Hodgkin lymphoma (including cutaneous lymphomas) orNon-Hodgkin lymphoma with variable FDG uptake and clinical course, such as mantlecell lymphoma; and measurable disease according to Lugano criteria

Histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD)
MGUS/SMM or MM according to IMWG definitions
Solid tumors, such as lung cancers, meningioma, adrenocortical neoplasms includingcortisol-producing adenomas or high suspicion for tumor, such as in patients withCushing's disease.
Age ≥18
Negative serum pregnancy test for female volunteers of childbearing age andpotential (as defined by MSKCC Standards & Guidelines) from assays obtained <2 weeksprior to study enrollment/intervention; or negative urine pregnancy test performedon the day of intervention
MSKCC patients

Exclusion

Exclusion Criteria:

Breast-feeding
History of renal functional disorders (chronic kidney disease with eGFR<30)
Refusal or inability to tolerate the scanning procedure (e.g., due toclaustrophobia)

Study Design